trending Market Intelligence /marketintelligence/en/news-insights/trending/vh-5sow0zflqopu2-9sexw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Edwards Lifesciences prevails in US review of Boston Scientific's patent claims

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Edwards Lifesciences prevails in US review of Boston Scientific's patent claims

The U.S. Patent and Trademark Office ruled in favor of Edwards Lifesciences Corp. in an inter partes review of Boston Scientific Corp.'s claims regarding its transcatheter heart valve.

The patent office decided that all the claims asserted against Edwards Lifesciences were invalid.

Boston Scientific had filed a patent case against Edwards Lifesciences in Delaware in 2016.

In March 2017, a U.K. patent court decided that a patent related to Edwards Lifesciences' Sapien 3 transcatheter heart valve infringed on a Boston Scientific patent.

Then in March 2017, a German district court ruled that Edwards Lifesciences' Sapien 3 transcatheter heart valve infringed on two patents of Boston Scientific's related to the seals for transcatheter heart valves.

Meanwhile, Edwards Lifesciences has asserted three of its own foundational transcatheter heart valve patents against Boston Scientific. These remain unaffected by the US patent office's decision and will continue to trial, which is expected later in 2018.

Irvine, Calif.-based Edwards Lifesciences provides products and technologies to treat heart diseases and for critical care monitoring.